BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Abbott (ABT): Contrarian sees healthy gains]]>http://www.bloggingstocks.com/2009/01/30/abbott-abt-contrarian-sees-healthy-gains/http://www.bloggingstocks.com/2009/01/30/abbott-abt-contrarian-sees-healthy-gains/http://www.bloggingstocks.com/2009/01/30/abbott-abt-contrarian-sees-healthy-gains/#commentsFiled under: , ,

"I think 2009 will be a very tough year for the economy but an exceptional year for stocks," says Alexander Green of The Oxford Club. Here, he looks at Abbott Laboratories (NYSE: ABT).

"The company has been around for more than 120 years. It currently operates in more than 130 countries, selling hundreds of products, including Ultane (an inhaled anesthetic), the anti-infective Biaxin XL, and TriCor and Niaspan to manage cholesterol.

"However, Abbott's biggest growth driver is Humira, a blockbuster drug that targets autoimmune disorders. The drug has received FDA approval to treat a number of diseases, including rheumatoid arthritis, psoriasis and Crohn's disease.

Continue reading Abbott (ABT): Contrarian sees healthy gains

Abbott (ABT): Contrarian sees healthy gains originally appeared on BloggingStocks on Fri, 30 Jan 2009 12:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>abbottabbott laboratoriesabtalex greendrug stockshealth stockshealthcare stocksHealthcareStocksmedical stocksMedicalStocksoxford clubOxfordClubpharmaceuticalsthestockadvisors.comFri, 30 Jan 2009 12:30:00 EST<![CDATA[Top Stock Picks '09: Amedisys (AMED)]]>http://www.bloggingstocks.com/2009/01/13/top-stock-picks-09-amedisys-amed/http://www.bloggingstocks.com/2009/01/13/top-stock-picks-09-amedisys-amed/http://www.bloggingstocks.com/2009/01/13/top-stock-picks-09-amedisys-amed/#commentsFiled under: ,

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Amedisys (NASDAQ: AMED), a provider of home health services," notes Richard Moroney, whose Upside Stocks newsletter uses a quantitative system to select high growth, smaller cap issues.

"The company operates more than 500 locations, focuses on Medicare-eligible patients because of favorable reimbursement rates as well as a large and growing patient base.

"The U.S. Census Bureau estimates that some 8,000 Americans will become Medicare eligible each day beginning in 2011. By 2030, nearly 58 million baby boomers will be eligible for Medicare benefits.

"In 2007, nearly 90% of the company's revenue was derived from Medicare. "Acquisitions and market-share gains should fuel strong results. In addition, Amedisys should benefit from an aging population beset by chronic illnesses.

"The company has developed specialized services that focus on high-cost diseases and chronic conditions. An estimated one-half of the U.S. population will have a chronic condition in 2020, or nearly 160 million people.

Continue reading Top Stock Picks '09: Amedisys (AMED)

Top Stock Picks '09: Amedisys (AMED) originally appeared on BloggingStocks on Tue, 13 Jan 2009 08:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>amedamedisyshealth stockshealthcare stockshome health care serviceshome health stocksmedical stocksmedicare stocksquantitative stocksrichard moroneysmall cap stocksupside stocksTue, 13 Jan 2009 08:00:00 EST